{"database":"biostudies-other","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Dr. Loretta, MS Lau"],"funding":["Department of Health, Australian Government | National Health and Medical Research Council (NHMRC)","University of New South Wales (UNSW)","Australian Cancer Research Foundation (ACRF)","Kids Cancer Project","Cancer Therapeutics Cooperative Research Centre (Cancer Therapeutics CRC)","Kids Cancer Alliance","Australian Lions Childhood Cancer Research Foundation (ALCCRF)","Cure Brain Cancer Foundation (CBCF)","Australian Federal Government","Robert Connor Dawes Foundation (RCD)","New South Wales State Government"],"journal":["EMBO Molecular Medicine"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-SCDT-EMM-2021-14608"],"abstract":["Biomarkers which better match anticancer drugs with cancer driver genes hold the promise of improved clinical responses and cure rates. We developed a precision medicine platform of rapid high-throughput drug screening (HTS) and patient-derived xenografting (PDX) of primary tumor tissue, and evaluated its potential for treatment identification among 56 consecutively enrolled high-risk pediatric cancer patients, compared with conventional molecular genomics and transcriptomics. Drug hits were seen in the majority of HTX and PDX screens, which identified therapeutic options for 10 patients for whom no targetable molecular lesions could be found. Screens also provided orthogonal proof of drug efficacy suggested by molecular analyses and negative results for some molecular findings. We identif"],"repository":["biostudies-other"],"funding_grant_id":["APP1157871","APP1059804"],"pubmed_authors":["Dong-Anh Khuong-Quang","Amit Kumar","Carol Wadham","Luciano Dalla-Pozza","Caitlin Ung","David, M Thomas","Meera Warby","Peter Trebilcock","Aaminah Khan","Richard, B Lock","Paulette Barahona","Murray, D Norris","Prof. Glenn, M Marshall","Marie Wong","Dr. Tim, W Failes","Mark Pinese","Vanessa Tyrrell","Andrew Gifford","Dr. Stephen, B Fox","Georgina Eden","Shu-Oi Chow","Elodie Manouvrier","Mrs. Chelsea Mayoh","Lisa, T Morgan","Federica Saletta","Prof. Jennifer, A Byrne","Dr. Greg, M Arndt","Stephanie Alfred","David, S Ziegler","Toby N. Trahair","Dylan Grebert Wade","Patrick, A Strong","Prof. Michelle Haber","Jinhan Xie","Geoffery, B McCowage","Dr. Loretta, MS Lau","Roxanne Cadiz","Karen, L MacKenzie","Anjana Gopalakrishnan","Prof. Mark Cowley","Alvin Kamili","Paul, G Ekert","Dr. Jamie Fletcher","Katherine, M Tucker","Emily, VA Mould","Andrew Fellowes","Maria Tsoli","Swapna Joshi"],"additional_accession":[]},"is_claimable":false,"name":"In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer","description":"Biomarkers which better match anticancer drugs with cancer driver genes hold the promise of improved clinical responses and cure rates. We developed a precision medicine platform of rapid high-throughput drug screening (HTS) and patient-derived xenografting (PDX) of primary tumor tissue, and evaluated its potential for treatment identification among 56 consecutively enrolled high-risk pediatric cancer patients, compared with conventional molecular genomics and transcriptomics. Drug hits were seen in the majority of HTX and PDX screens, which identified therapeutic options for 10 patients for whom no targetable molecular lesions could be found. Screens also provided orthogonal proof of drug efficacy suggested by molecular analyses and negative results for some molecular findings. We identif","dates":{"release":"2022-07-18T00:00:00Z","modification":"2022-07-18T16:44:23.982Z","creation":"2022-07-18T16:44:23.982Z"},"accession":"S-SCDT-EMM-2021-14608","cross_references":{"doi":["10.15252/emmm.202114608"]}}